龙源期刊网 http://www.qikan.com.cn
替格瑞洛对急性心肌梗死PCI术后TIMI血流分级及血小板的影响
作者：孟红社
来源：《上海医药》2018年第05期
摘 要 目的：探讨替格瑞洛对急性心肌梗死经皮冠脉介入治疗（PCI）术后TIMI血流分级及血小板的影响。方法：选取我院收治的择期行PCI术的急性心肌梗死患者80例，根据随机数字表法将所有患者分为两组，每组各40例。给予对照组患者氯吡格雷治疗，观察组患者替格瑞洛治疗，比较两组患者TIMI血流分级、血小板聚集率及心血管不良事件发生率。结果：治疗后，两组患者TIMI血流分级、血小板聚集率及心血管不良事件发生率相比，观察组均优于对照组（P
关键词 急性心肌梗死 替格瑞洛 经皮冠脉介入治疗
中图分类号：R973.2； R542.22 文献标识码：B 文章编号：1006-1533（2018）05-0029-03 Effects of ticagrelor on TIMI flow classification and platelet in patients with acute myocardial infarction after percutaneous coronary intervention MENG Hongshe
（The Second People’s Hospital of Nanyang City， Nanyang 473000， China）
ABSTRACT Objective： To investigate the effect of ticagrelor on TIMI flow classification and platelet after percutaneous coronary intervention （PCI） in patients with acute myocardial infarction. Methods： Eighty patients with acute myocardial infarction undergoing elective PCI were enrolled and divided into an observation group and a control group with 40 cases each based on the random number table. Patients were treated with clopidogrel in the control group and ticagrelor in the observation group. TIMI flow classification， platelet aggregation rate and the incidence of cardiovascular adverse events were compared between the two groups. Results： These indicators were much better in the observation group than in the control group after treatment （P
KEY WORDS acute myocardial infarction； ticagrelor； percutaneous coronary intervention 急性心肌梗死是临床较为常见的一种危重症，临床患病率高，且并发症多，患者需及时接受治疗，将患者血管疏通，确保心肌血液循环是挽救患者生命的关键[1]。经皮冠脉介入治疗（PCI）是临床治疗急性心肌梗死的首选治疗方案，而术前给予患者抗血小板药物是提高手术治疗效果的关键，因此寻求高效的抗血小板药物至关重要[2-3]。本研究探究替格瑞洛对急性心肌梗死PCI术后TIMI血流分级及血小板的影响。
替格瑞洛对急性心肌梗死PCI术后TIMI血流分级及血小板的影响
